Hyzaar/Hyzaar Plus/Hyzaar Forte

Hyzaar/Hyzaar Plus/Hyzaar Forte

losartan + hydrochlorothiazide

Manufacturer:

MSD

Distributor:

Zuellig
/
Agencia Lei Va Hong

Marketer:

A. Menarini
Concise Prescribing Info
Contents
Per Hyzaar tab Losartan K 50 mg, hydrochlorothiazide 12.5 mg. Per Hyzaar Plus tab Losartan K 100 mg, hydrochlorothiazide 12.5 mg. Per Hyzaar Forte tab Losartan K 100 mg, hydrochlorothiazide 25 mg
Indications/Uses
HTN where combination therapy is appropriate. Reduce risk of stroke in hypertensive patients w/ left ventricular hypertrophy.
Dosage/Direction for Use
HTN 1 Hyzaar tab once daily, can be increased after 3 wk to a max of 1 Hyzaar Forte tab, or 2 Hyzaar tab once daily. Patients whose BP is inadequately controlled w/ losartan 50 mg monotherapy 1 Hyzaar tab once daily, may be increased after about 3 wk to 2 Hyzaar tab once daily, or 1 Hyzaar Forte tab once daily. Patients whose BP is inadequately controlled w/ losartan 100 mg monotherapy 1 Hyzaar Plus tab once daily. If uncontrolled after about 3 wk, increase dose to 2 Hyzaar tab once daily, or 1 Hyzaar Forte tab once daily. Patients whose BP is inadequately controlled w/ hydrochlorothiazide 25 mg once daily or is controlled but experiences hypokalemia 1 Hyzaar tab once daily. If uncontrolled after about 3 wk, increase to 2 Hyzaar tab once daily, or 1 Hyzaar Forte tab once daily. Hypertensive patient w/ left ventricular hypertrophy Patients whose BP is inadequately controlled on losartan 50 mg Initiate w/ Hyzaar tab. Increase dose to Hyzaar Plus, followed by Hyzaar Forte if additional BP reduction is needed.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Anuria. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2).
Special Precautions
Symptomatic hypotension after treatment initiation in patients w/ activated renin-angiotensin system. Changes in renal function including acute renal failure. Antihypertensive effects may be enhanced in post-sympathectomy patient. Dual blockade of the renin-angiotensin-aldosterone system. Patients w/ severe renal impairment. Not recommended for patients w/ hepatic impairment. Fetal toxicity. Pregnancy & lactation. Ped patients. Hydrochlorothiazide: Increased probability of hypersensitivity reaction in patients w/ history of allergy or bronchial asthma. Risk of hypokalemia, hyponatremia & hypomagnesemia; altered glucose tolerance & raised serum levels of cholesterol & triglycerides; hyperuricemia, frank gout; decreased urinary Ca excretion, elevated serum Ca; idiosyncratic reaction resulting in acute transient myopia & acute angle-closure glaucoma; exacerbation or activation of SLE.
Adverse Reactions
Back pain, dizziness, upper resp tract infection. Anemia, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis; anorexia, hyperglycemia, hyperuricemia, electrolyte imbalance including hyponatremia & hypokalemia; insomnia, restlessness; dysgeusia, headache, migraine, paraesthesias; xanthopsia, transient blurred vision; palpitation, tachycardia; dose-related orthostatic effects, necrotizing angiitis; nasal congestion, pharyngitis, sinus disorder, resp distress; dyspepsia, abdominal pain, gastric irritation, cramping, diarrhea, constipation, nausea, vomiting, pancreatitis, sialoadenitis; jaundice; rash, pruritus, purpura, toxic epidermal necrolysis, urticaria, photosensitivity, cutaneous lupus erythematosus; muscle cramps, muscle spasm, myalgia, arthralgia; glycosuria, renal dysfunction, interstitial nephritis, renal failure; erectile dysfunction/impotence; chest pain, edema/swelling, malaise, fever, weakness; liver function abnormalities.
Drug Interactions
Increased serum conc & toxicity of lithium. Risk of renal function deterioration & attenuated effect w/ NSAIDs including selective COX-2 inhibitors. Higher frequency of adverse events through combined use of angiotensin II receptor blockers, ACE inhibitors, or aliskiren. Losartan: Hyperkalemia w/ other drugs that raise serum K levels. Hydrochlorothiazide: Dose adjustment of antidiabetic drug may be required. Impaired absorption w/ anionic exchange resins (eg, cholestyramine or colestipol resins).
ATC Classification
C09DA01 - losartan and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Hyzaar Forte tab
Packing/Price
30's
Form
Hyzaar Plus tab
Packing/Price
30's
Form
Hyzaar tab
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in